3 health care stocks to sell
J&J and Pfizer are among the sector's duds.
By Louis Navellier, editor of Blue Chip Growth
Health care stocks are a vital part of most investors' portfolios.
The theory goes that people will always get sick, so these companies will
always have healthy profits.
Well, unfortunately, some rough quarterly earnings reports and dips in share values in recent weeks have proved that even the health care sector is subject to some volatility and that no earnings are guaranteed.
Here are three pharma and medical blue chips that have not lived up to expectations and are hazardous to the health of your portfolio:
Amgen. (AMGN) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses focusing on human therapeutics and medicines based on advances in cellular and molecular biology. Its current quarter growth estimate is at -14.8% and AMGN sales were slightly down with some of the big name drugs in its catalog. Amgen is a better bet as a sell than a hold.
Gilead Sciences. (GILD) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. The Company products include Truvada, Atripla, Viread, and Emtriva. Coming off a quarter with lower than expected revenue stream, GILD is also in the wake of a negative earnings report and shares have dropped more than -20% year-to-date. Don’t let Gilead infect the rest of your portfolio as it rides out its unhealthy wave.
Celgene. (CELG) is an integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. With stock returns down -9.4% in the past three months and the company slow to gain momentum, the future for CELG shares present a high risk threat.For 8 more health care stocks to sell, follow the link for the full story.
Related Articles:
MORE ON MSN MONEY
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
STOCK SCOUTER
StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.
125 | 272 | 424 | 589 | 697 | 589 | 666 | 435 | 260 | 144 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
LATEST POSTS
The auto parts giant beats Wall Street expectations, while continuing to expand its stores in the U.S. and Mexico.
FIDELITY VIEWPOINTS
- How to sell covered calls - Fidelity Investments
- Savvy year-end tax moves to consider now - Fidelity Investments
- Seven ways to prepare for tax changes
- Five reasons an annual review is crucial - Fidelity Investments
- Take a look at mid caps now - Fidelity Investments
- State of the sector: Health care - Fidelity Investments
VIDEO ON MSN MONEY
ABOUT
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.